AIOS Scales GLP-1 via UK Pharmacy

AIOS has shown that GLP-1 telehealth can scale like consumer internet when the company controls the patient funnel and can slot demand into the cheapest legal drug channel. The jump from $125M annualized gross revenue at the end of 2025 to $450M by August 2026 came from shifting after the US compounding crackdown into the UK, where Bolt let AIOS sell branded Wegovy and Mounjaro at cost, win on price, and turn paid ads plus a simple online intake flow into a 150,000 patient machine.1 2

• This is a pharmacy revenue story more than a software margin story. In the UK, AIOS takes little or no markup on the drug itself, so most revenue passes through to Lilly and Novo. That can produce very fast top line growth, but at roughly 20% gross margins, far below the 65% to 80% range seen at more vertically integrated telehealth players like Ro and Hims & Hers.1 2
• The operating model is simple and repeatable. AIOS buys traffic, gets patients through a short questionnaire, routes them to a licensed prescriber, ships medication monthly, and manages dose changes and refills in one workflow. That means revenue can rise quickly with ad spend and pharmacy capacity, rather than with opening clinics or hiring large in person care teams.1
• AIOS is taking the opposite path from Hims & Hers and Ro. Instead of stacking many conditions under one broad brand, it is concentrating on one hero product, GLP-1s, then stretching that across segments and geographies through Fella, Delilah, and Bolt. That focus helps it move faster in obesity care, but also ties the company more tightly to GLP-1 pricing, supply, and regulation.1 3 4

The next phase is about turning a fast growing reseller into a lower cost drug and pharmacy network. If AIOS can repeat the Bolt model across Europe, then eventually add generic semaglutide manufacturing as patents expire in the early 2030s, more of each prescription dollar can stay inside the company instead of flowing through to drug makers.1 3